CARDIOVASCULAR COMPLICATIONS OF ESTROGEN THERAPY FOR NONDISSEMINATED PROSTATIC-CARCINOMA - A PRELIMINARY-REPORT FROM A RANDOMIZED MULTICENTER STUDY

被引：19
|
作者：
LUNDGREN, R
SUNDIN, T
COLLEEN, S
LINDSTEDT, E
WADSTROM, L
CARLSSON, S
HELLSTEN, S
POMPEIUS, R
HOLMQUIST, B
NILSSON, T
RUBIN, S
LUTTROPP, W
JANSEN, H
机构：
[1] HELSINGBORG CENT HOSP,DEPT UROL,LUND,SWEDEN
[2] UNIV HOSP MALMO,DEPT UROL,MALMO,SWEDEN
来源：
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY | 1986年 / 20卷 / 02期
关键词：
D O I：
10.3109/00365598609040556
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 105
页数：5
相关论文
共 50 条
  • [41] Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N-0 M(0) prostatic carcinoma
    Witjes, WPJ
    Schulman, CC
    Debruyne, FMJ
    UROLOGY, 1997, 49 (3A) : 65 - 69
  • [42] Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
    Katz, Matthew H. G.
    Varadhachary, Gauri R.
    Bauer, Todd W.
    Acquavella, Nicolas
    Merchant, Nipun B.
    Le, Tri Minh
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] A multicenter phase II study of local radiation therapy for stage iea mucosa-associated lymphoid tissue lymphomas: A preliminary report from the japan radiation oncology group (jarog)
    Isobe, Koichi
    Kagami, Yoshikazu
    Higuchi, Keiko
    Kodaira, Takeshi
    Hasegawa, Masatoshi
    Shikama, Naoto
    Nakazawa, Masanori
    Fukuda, Ichiro
    Nihei, Keiji
    Ito, Kana
    Teshima, Teruki
    Matsuno, Yoshihiro
    Oguchi, Masahiko
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04): : 1181 - 1186
  • [44] Pegylated (40 kDa) interferon alta-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that did not respond to Rebetron® therapy:: A preliminary report of a randomized, multicenter study
    Afdhal, N
    Flamm, S
    Imperial, J
    Malet, PF
    Tong, M
    Campagna, J
    Pappas, SC
    GASTROENTEROLOGY, 2001, 120 (05) : A383 - A383
  • [45] Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck, a randomized multicenter study of 5 versus 6 fractions per week - Report from the dahanca 7 trial.
    Overgaard, J
    Hansen, HS
    Overgaard, M
    Bastholt, L
    Specht, L
    Evensen, J
    Pedersen, M
    Grau, C
    Jorgensen, K
    Hansen, O
    Sapru, W
    Berthelsen, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 188 - 188
  • [46] Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that relapsed on Rebetron™ therapy:: A preliminary report of a randomized, multicenter efficacy and safety study
    Herrine, SK
    Brown, R
    Esposito, S
    Lok, A
    Galati, JS
    Bernstein, DE
    Campagna, J
    Pappas, SC
    GASTROENTEROLOGY, 2001, 120 (05) : A384 - A384
  • [47] A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report
    Kim, S.
    Khushalani, N. I.
    Eroglu, Z.
    Russell, J.
    Wuthrick, E.
    Caudell, J.
    Harrison, L.
    Aoki, M.
    Shah, H.
    Blakaj, D.
    Markowitz, J.
    Chen, D-T.
    Messina, J.
    Rose, T.
    Tsai, K.
    Brohl, A. S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC) - a preliminary report.
    Wood, CG
    Escudier, B
    Gorelov, S
    Krajka, K
    Lacombe, L
    Fossa, S
    Hoos, A
    Flanigan, R
    Figlin, R
    Srivastava, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 192S - 192S
  • [49] Progression of Lower Urinary Tract Symptoms After Discontinuation of 1 Medication From 2-Year Combined Alpha-blocker and 5-Alpha-reductase Inhibitor Therapy for Benign Prostatic Hyperplasia in Men - A Randomized Multicenter Study
    Lin, Victor Chia-Hsiang
    Liao, Chun-Hou
    Kuo, Hann-Chorng
    UROLOGY, 2014, 83 (02) : 416 - 421
  • [50] RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study
    Motzer, R. J.
    Escudier, B.
    Oudard, S.
    Porta, C.
    Hutson, T. E.
    Bracarda, S.
    Hollaender, N.
    Urbanowitz, G.
    Kay, A.
    Ravaud, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345